Table 2.
Patients’ characteristics and efficacy in patients from the retrospective studies. The third and fourth columns contain information on the total number of patients and the number of series the result depicted in the second column is based on. Percentages may not add up to 100 because of different denominators due to variable groupings or missing information in the pooled studies.
| Patients (%) | Total Patients with Data | Number of Series with Data |
|
|---|---|---|---|
| Age (median, range) | 55–73 (26–83) | 441 | 8 |
| SEX | |||
| Male | 233 (52.8%) | 441 | 8 |
| Female | 208 (47.2%) | ||
| ECOG PS | |||
| 0–1 | 388 (92.4%) | 420 | 7 |
| >1 | 32 (7.6%) | ||
| NUMBER OF PRIOR LINES OF CHEMO | |||
| 1–2 | 134 (53.8%) | 249 | 5 |
| >2 | 115 (46.2%) | ||
| Range numbers | 1–>4 | ||
| TYPES OF PRIOR CHEMOTHERAPY |
|||
| Fluoropyrimidine | 354 (100%) | 354 | 5 |
| Irinotecan | 338 (95.5%) | 354 | 5 |
| Oxaliplatin | 350 (98.9%) | 354 | 5 |
| Anti-angiogenic | 376 (95.7%) | 393 | 7 |
| Anti-EGFR | 115 (32.5%) | 354 | 5 |
| LOCATION OF PRIMARY | |||
| Colon (side not specified) | 31 (57.4%) | 54 | 1 |
| Right-sided colon | 98 (25.7%) | 382 | 7 |
| Left-sided colon | 24 (27.6%) | 87 | 3 |
| Left-sided colon and rectum | 227 (75.7%) | 300 | 4 |
| Rectum | 41 (37.3%) | 110 | 3 |
| NUMBER OF ORGANS INVOLVED | |||
| 1 | 81 (25.2%) | 321 | 5 |
| 2 | 72 (41.4%) | 174 | 2 |
| 1–2 | 22 (62.9%) | 35 | 1 |
| ≥2 | 118 (80.3%) | 147 | 3 |
| ≥3 | 63 (30.1%) | 209 | 3 |
| SITES INVOLVED | |||
| Lung | 219 (64.6%) | 339 | 5 |
| Liver | 213 (62.8%) | 339 | 5 |
| Peritoneum | 96 (28.3%) | 339 | 5 |
| Lymph nodes | 77 (45.6%) | 169 | 3 |
| SURGERY FOR PRIMARY | |||
| Yes | 187 (72.5%) | 258 | 5 |
| No | 71 (27.5%) | 258 | 5 |
| EFFICACY | |||
| Median OS (months) (95% CI) | 11.17 (10.15–12.19) | 437 | 8 |
| Median PFS (months) (95% CI) | 4.56 (3.57–5.55) | 416 | 7 |
| RR% (95% CI) | 2.71 (1.11–4.32) | 405 | 7 |
| CBR% (95% CI) | 59.63 (52.06–67.21) | 405 | 7 |